On Tuesday July 25th one of the oral poster presentations at IAS 2017 was Antiretroviral Therapy – ART: Season Two

Five presentations were presented:

1. Darunavir/Cobicistat/Entricitabine/TAF The First Once Daily STR in Development Containing Darunavir

2. Dual Therapy with Protease Inhibitors and Lamivudine

3. Doravirine/Lamivudine/TDF to  Show Non-inferiority To Efavirenz/TDF/Emtricitabine

4. Superior Efficacy of Dolutegravir + 2NRTI compared with Lopinavir/r + 2NRTI

5. HIV Specific Broadly Neutralizing Monoclonal Antibody VRCo1 Impacts Time To Virological rebound Following Treatment Interruption in Virologically Suppressed HIV Infected Participants Who Initiated Antiretroviral Therapy During Acute HIV Infection

Watch the presentation here:

#IAS2017  #MichRxConsulting